JP2021506778A5 - - Google Patents

Download PDF

Info

Publication number
JP2021506778A5
JP2021506778A5 JP2020531978A JP2020531978A JP2021506778A5 JP 2021506778 A5 JP2021506778 A5 JP 2021506778A5 JP 2020531978 A JP2020531978 A JP 2020531978A JP 2020531978 A JP2020531978 A JP 2020531978A JP 2021506778 A5 JP2021506778 A5 JP 2021506778A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
cd45rc
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020531978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506778A (ja
Filing date
Publication date
Priority claimed from EP17306783.6A external-priority patent/EP3498293A1/en
Application filed filed Critical
Publication of JP2021506778A publication Critical patent/JP2021506778A/ja
Publication of JP2021506778A5 publication Critical patent/JP2021506778A5/ja
Priority to JP2022201777A priority Critical patent/JP7562058B2/ja
Pending legal-status Critical Current

Links

JP2020531978A 2017-12-15 2018-12-14 抗ｃｄ４５ｒｃ抗体を用いる単一遺伝子疾患の処置 Pending JP2021506778A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022201777A JP7562058B2 (ja) 2017-12-15 2022-12-19 抗ｃｄ４５ｒｃ抗体を用いる単一遺伝子疾患の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306783.6A EP3498293A1 (en) 2017-12-15 2017-12-15 Treatment of monogenic diseases with an anti-cd45rc antibody
EP17306783.6 2017-12-15
PCT/EP2018/085016 WO2019115791A1 (en) 2017-12-15 2018-12-14 Treatment of monogenic diseases with an anti-cd45rc antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022201777A Division JP7562058B2 (ja) 2017-12-15 2022-12-19 抗ｃｄ４５ｒｃ抗体を用いる単一遺伝子疾患の処置

Publications (2)

Publication Number Publication Date
JP2021506778A JP2021506778A (ja) 2021-02-22
JP2021506778A5 true JP2021506778A5 (cg-RX-API-DMAC7.html) 2021-12-23

Family

ID=60923326

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020531978A Pending JP2021506778A (ja) 2017-12-15 2018-12-14 抗ｃｄ４５ｒｃ抗体を用いる単一遺伝子疾患の処置
JP2022201777A Active JP7562058B2 (ja) 2017-12-15 2022-12-19 抗ｃｄ４５ｒｃ抗体を用いる単一遺伝子疾患の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022201777A Active JP7562058B2 (ja) 2017-12-15 2022-12-19 抗ｃｄ４５ｒｃ抗体を用いる単一遺伝子疾患の処置

Country Status (9)

Country Link
US (1) US20210163593A1 (cg-RX-API-DMAC7.html)
EP (2) EP3498293A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021506778A (cg-RX-API-DMAC7.html)
CN (1) CN111801118B (cg-RX-API-DMAC7.html)
AU (1) AU2018383016B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020011949A2 (cg-RX-API-DMAC7.html)
CA (1) CA3085843A1 (cg-RX-API-DMAC7.html)
MA (1) MA51136A (cg-RX-API-DMAC7.html)
WO (1) WO2019115791A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
US20230147657A1 (en) 2020-03-20 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
IL307902A (en) * 2021-04-26 2023-12-01 Regenxbio Inc Microdystrophin gene therapy administration for treatment of dystrophinopathies
PL4401842T3 (pl) 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CA3240875A1 (en) 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
CN115671287B (zh) * 2022-10-31 2023-11-10 浙江大学 Feingold综合征Ι型治疗药物及其应用
EP4637928A1 (en) 2022-12-23 2025-10-29 Cimeio Therapeutics AG Antibodies targeting cd45

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
AU2002309063B8 (en) 2001-05-11 2008-04-24 Kyowa Kirin Co., Ltd. Artificial human chromosome containing human antibody lambda light chain gene
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
KR101703299B1 (ko) 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
AU2009303526B2 (en) 2008-10-14 2015-01-15 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
US20170226209A1 (en) * 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl

Similar Documents

Publication Publication Date Title
JP5129122B2 (ja) 癌治療のための抗体およびグルココルチコイドの組み合わせ
KR20190108144A (ko) 질환 및 장애의 치료 및 방지를 위한 단쇄 지방산의 용도
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
JP2018516969A5 (cg-RX-API-DMAC7.html)
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
Stallmach et al. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo
JP2009533367A5 (cg-RX-API-DMAC7.html)
JP2019515008A5 (cg-RX-API-DMAC7.html)
JP2018519327A (ja) 治療用組成物、組合せ物および使用の方法
TW201024310A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
JP2008540447A5 (cg-RX-API-DMAC7.html)
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
JP2020503269A5 (cg-RX-API-DMAC7.html)
US12234293B2 (en) Treatment for primary amyloidosis with anti-BCMA binding protein
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
TWI794823B (zh) 包含比替拉韋(bictegravir)之醫藥組合物
JP2019070056A5 (cg-RX-API-DMAC7.html)
EP2838568A2 (en) Immunomodulation by anti-cd3 immunotoxins to treat cancers not uniformly bearing surface cd3
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
BR112020005077A2 (pt) tratamento de combinação para câncer
CN1512886A (zh) 抗孕激素预防和治疗激素依赖性疾病的用途
Lascano et al. Management of ulcerative colitis in the morbidly obese patient: is bariatric surgery indicated?
RU2006113701A (ru) Лечение респираторных заболеваний антителами против рецептора il-2
JP4398731B2 (ja) 関節リウマチの処置
Baughman et al. Therapy for extrapulmonary sarcoidosis